Christopher Elias, M.D., M.P.H., John N. Nkengasong, Ph.D., and Firdausi Qadri, Ph.D.
doi : 10.1056/NEJMp2034517
N Engl J Med 2021; 384:1181-1184
Kellan E. Baker, Ph.D., M.P.H., Carl G. Streed, Jr., M.D., M.P.H., and Laura E. Durso, Ph.D.
doi : 10.1056/NEJMp2032447
N Engl J Med 2021; 384:1184-1186
Perri Klass, M.D.
doi : 10.1056/NEJMp2032451
N Engl J Med 2021; 384:1186-1189
Ronan J. Kelly, M.B., B.Ch., M.B.A., Jaffer A. Ajani, M.D., Jaroslaw Kuzdzal, M.D., Ph.D., Thomas Zander, M.D., Eric Van Cutsem, M.D., Ph.D., Guillaume Piessen, M.D., Ph.D., Guillermo Mendez, M.D., Josephine Feliciano, M.D., Satoru Motoyama, M.D., Ph.D., Astrid Lièvre, M.D., Ph.D., Hope Uronis, M.D., Elena Elimova, M.D., Cecile Grootscholten, M.D., Ph.D., Karen Geboes, M.D., Ph.D., Syed Zafar, M.D., Stephanie Snow, M.D., Andrew H. Ko, M.D., Kynan Feeney, M.D., Michael Schenker, M.D., Ph.D., Piotr Kocon, M.D., Ph.D., Jenny Zhang, M.D., Ph.D., Lili Zhu, Ph.D., Ming Lei, Ph.D., Prianka Singh, Pharm.D., M.P.H., Kaoru Kondo, M.Sc., James M. Cleary, M.D., Ph.D., and Markus Moehler, M.D., Ph.D. for the CheckMate 577 Investigators*
doi : 10.1056/NEJMoa2032125
N Engl J Med 2021; 384:1191-1203
No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer.
Marc Humbert, M.D., Ph.D., Vallerie McLaughlin, M.D., J. Simon R. Gibbs, M.D., Mardi Gomberg-Maitland, M.D., Marius M. Hoeper, M.D., Ioana R. Preston, M.D., Rogerio Souza, M.D., Ph.D., Aaron Waxman, M.D., Ph.D., Pilar Escribano Subias, M.D., Ph.D., Jeremy Feldman, M.D., Gisela Meyer, M.D., David Montani, M.D., Ph.D., Karen M. Olsson, M.D., Solaiappan Manimaran, Ph.D., Jennifer Barnes, Ph.D., Peter G. Linde, M.D., Janethe de Oliveira Pena, M.D., Ph.D., and David B. Badesch, M.D. for the PULSAR Trial Investigators*
doi : 10.1056/NEJMoa2024277
N Engl J Med 2021; 384:1204-1215
Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling, cellular proliferation, and poor long-term outcomes. Dysfunctional bone morphogenetic protein pathway signaling is associated with both hereditary and idiopathic subtypes. Sotatercept, a novel fusion protein, binds activins and growth differentiation factors in the attempt to restore balance between growth-promoting and growth-inhibiting signaling pathways.
Sander F. Garrelfs, M.D., Yaacov Frishberg, M.D., Sally A. Hulton, M.D., Michael J. Koren, M.D., William D. O’Riordan, M.D., Pierre Cochat, M.D., Ph.D., Georges Deschênes, M.D., Ph.D., Hadas Shasha-Lavsky, M.D., Jeffrey M. Saland, M.D., William G. van’t Hoff, M.D., Daniel G. Fuster, M.D., Daniella Magen, M.D., Shabbir H. Moochhala, M.B., Ch.B., Ph.D., Gesa Schalk, M.D., Eva Simkova, M.D., Jaap W. Groothoff, M.D., Ph.D., David J. Sas, D.O., Kristin A. Meliambro, M.D., Jiandong Lu, Ph.D., Marianne T. Sweetser, M.D., Ph.D., Pushkal P. Garg, M.D., Akshay K. Vaishnaw, M.D., Ph.D., John M. Gansner, M.D., Ph.D., Tracy L. McGregor, M.D., and John C. Lieske, M.D. for the ILLUMINATE-A Collaborators*
doi : 10.1056/NEJMoa2021712
N Engl J Med 2021; 384:1216-1226
Primary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by hepatic overproduction of oxalate that leads to kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. Lumasiran, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase.
Iain B. McInnes, F.R.C.P., Jaclyn K. Anderson, D.O., Marina Magrey, M.D., Joseph F. Merola, M.D., Yi Liu, M.D., Mitsumasa Kishimoto, M.D., Slawomir Jeka, M.D., Cesar Pacheco-Tena, M.D., Ph.D., Xin Wang, Ph.D., Liang Chen, M.S., Patrick Zueger, Pharm.D., Ph.D., John Liu, M.D., Aileen L. Pangan, M.D., and Frank Behrens, M.D.
doi : 10.1056/NEJMoa2022516
N Engl J Med 2021; 384:1227-1239
The Janus kinase inhibitor upadacitinib is a potential treatment for psoriatic arthritis. The efficacy and safety of upadacitinib as compared with adalimumab, a tumor necrosis factor ? inhibitor, in patients who have an inadequate response to nonbiologic disease-modifying antirheumatic drugs are unclear.
Placide Mbala-Kingebeni, M.D., Ph.D., Catherine Pratt, M.Sc., Mbusa Mutafali-Ruffin, M.D., Matthias G. Pauthner, Ph.D., Faustin Bile, M.D., Antoine Nkuba-Ndaye, M.D., Allison Black, Ph.D., Eddy Kinganda-Lusamaki, M.D., Martin Faye, Ph.D., Amuri Aziza, M.Sc., Moussa M. Diagne, Ph.D., Daniel Mukadi, M.D., Bailey White, B.Sc., James Hadfield, Ph.D., Karthik Gangavarapu, B.Pharm., Nella Bisento, M.Sc., Donatien Kazadi, M.D., Bibiche Nsunda, B.Sc., Marceline Akonga, B.Sc., Olivier Tshiani, M.D., John Misasi, M.D., Aurelie Ploquin, Ph.D., Victor Epaso, M.D., Emilia Sana-Paka, M.D., Yannick Tutu Tshia N’kasar, M.D., Fabrice Mambu, M.D., Francois Edidi, M.D., Meris Matondo, M.D., Junior Bula Bula, M.D., Boubacar Diallo, M.D., Mory Keita, M.D., Marie R.D. Belizaire, M.D., Ibrahima S. Fall, Ph.D., Abdoulaye Yam, M.D., Sabue Mulangu, M.D., Anne W. Rimion, Ph.D., M.P.H., Elias Salfati, Ph.D., Ali Torkamani, Ph.D., Marc A. Suchard, M.D., Ph.D., Ian Crozier, M.D., Lisa Hensley, Ph.D., Andrew Rambaut, Ph.D., Ousmane Faye, Ph.D., Amadou Sall, Ph.D., Nancy J. Sullivan, Ph.D., Trevor Bedford, Ph.D., Kristian G. Andersen, Ph.D., Michael R. Wiley, Ph.D., Steve Ahuka-Mundeke, M.D., Ph.D., and Jean-Jacques Muyembe Tamfum, M.D., Ph.D.
doi : 10.1056/NEJMoa2024670
N Engl J Med 2021; 384:1240-1247
During the 2018–2020 Ebola virus disease (EVD) outbreak in North Kivu province in the Democratic Republic of Congo, EVD was diagnosed in a patient who had received the recombinant vesicular stomatitis virus–based vaccine expressing a ZEBOV glycoprotein (rVSV-ZEBOV) (Merck). His treatment included an Ebola virus (EBOV)–specific monoclonal antibody (mAb114), and he recovered within 14 days. However, 6 months later, he presented again with severe EVD-like illness and EBOV viremia, and he died. We initiated epidemiologic and genomic investigations that showed that the patient had had a relapse of acute EVD that led to a transmission chain resulting in 91 cases across six health zones over 4 months. (Funded by the Bill and Melinda Gates Foundation and others.)
Rita R. Kalyani, M.D.
doi : 10.1056/NEJMcp2000280
N Engl J Med 2021; 384:1248-1260
Thamonwan Norasethasopon, M.D., and Lakkana Boonyagars, M.D.
doi : 10.1056/NEJMicm2032478
N Engl J Med 2021; 384:1261
Radwan Kassir, M.D., Ph.D.
doi : 10.1056/NEJMicm2028463
N Engl J Med 2021; 384:e49
Daniel J. Minter, M.D., Megan Richie, M.D., Priya Kumthekar, M.D., and Harry Hollander, M.D.
doi : 10.1056/NEJMcps2028560
N Engl J Med 2021; 384:1262-1267
David H. Ilson, M.D., Ph.D.
doi : 10.1056/NEJMe2101983
N Engl J Med 2021; 384:1269-1271
John H. Newman, M.D.
doi : 10.1056/NEJMe2036314
N Engl J Med 2021; 384:1271-1272
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., Carlos Del Rio, M.D., Chidiebere Akusobi, Ph.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2105496
N Engl J Med 2021; 384:e60
doi : 10.1056/NEJMc2102131
N Engl J Med 2021; 384:1273-1277
doi : 10.1056/NEJMc2101321
N Engl J Med 2021; 384:1278
doi : 10.1056/NEJMc2101283
N Engl J Med 2021; 384:e51
doi : 10.1056/NEJMx200014
N Engl J Med 2021; 384:1278
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟